Evidence map›Paper›PMID 35632774›Full record

Trial reportViruses2022

Efficacy of the Sentinox Spray in Reducing Viral Load in Mild COVID-19 and Its Virucidal Activity against Other Respiratory Viruses: Results of a Randomized Controlled Trial and an In Vitro Study.

Donatella Panatto, Andrea Orsi, Bianca Bruzzone, Valentina Ricucci, Guido Fedele, Giorgio Reiner, Nadia Giarratana, Alexander Domnich, Giancarlo Icardi, Stx Study Group

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04909996 (Post-market, Confirmatory, Interventional, Randomized and Controlled Clinical Study to Assess the Efficacy and Safety of Sentinox in COVID-19 Patients.), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04909996 nacompletednot on this map

Post-market, Confirmatory, Interventional, Randomized and Controlled Clinical Study to Assess the Efficacy and Safety of Sentinox in COVID-19 Patients.

TypeinterventionalSponsorAPR Applied Pharma Research s.a.Ran2021 to 2021Enrolled57ConditionsCOVID-19 (SARS-CoV-2 Infection)ArmsSentinox--Group A, Sentinox--Group B
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Donatella PanattoDepartment of Health Sciences (DISSAL), University of Genoa, 16132 Genoa, Italy.ORCID 0000-0002-2677-0551
Andrea OrsiDepartment of Health Sciences (DISSAL), University of Genoa, 16132 Genoa, Italy.ORCID 0000-0002-2433-9610
Bianca BruzzoneHygiene Unit, San Martino Policlinico Hospital-IRCCS for Oncology and Neurosciences, 16132 Genoa, Italy.
Valentina RicucciHygiene Unit, San Martino Policlinico Hospital-IRCCS for Oncology and Neurosciences, 16132 Genoa, Italy.
Guido FedeleNG Scientific Consulting, 20091 Bresso, Italy.
Giorgio ReinerAPR Applied Pharma Research SA, via Corti 5, CH-6828 Balerna, Switzerland.
Nadia GiarratanaAPR Applied Pharma Research SA, via Corti 5, CH-6828 Balerna, Switzerland.ORCID 0000-0001-9154-6057
Alexander DomnichHygiene Unit, San Martino Policlinico Hospital-IRCCS for Oncology and Neurosciences, 16132 Genoa, Italy.ORCID 0000-0001-9608-8892
Giancarlo IcardiDepartment of Health Sciences (DISSAL), University of Genoa, 16132 Genoa, Italy.ORCID 0000-0002-8463-8487
Stx Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sentinox (STX) is an acid-oxidizing solution containing hypochlorous acid in spray whose virucidal activity against SARS-CoV-2 has been demonstrated. In this paper, results of a randomized controlled trial (RCT) on the efficacy of STX in reducing viral load in mild COVID-19 patients (NCT04909996) and a complementary in vitro study on its activity against different respiratory viruses are reported. In the RCT, 57 patients were randomized (1:1:1) to receive STX three (STX-3) or five (STX-5) times/day plus standard therapy or standard therapy only (controls). Compared with controls, the log

Indexed as

COVID-19 Drug TreatmentVirusesHumansSARS-CoV-2Serologic TestsViral LoadCOVID-19efficacyhypochlorous acidrandomized controlled trialrespiratory virusesSARS-CoV-2Sentinoxviral load

Identifiers

PMID35632774
PMCPMC9144724

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.